Abstract
Glucagon like peptide-1 (GLP-1) is one of the gastrointestinal peptides implicated in glycaemic homeostasis. In non-obese individuals with normal glucose tolerance GLP-1 is secreted in response to nutrient intake. However, this GLP- 1 response is generally accepted to be significantly diminished in those with diabetes, obesity or both.
Given that GLP-1 is secreted from enteroendocrine L cells in the intestine, it is not surprising that manipulation of the gastro- intestinal tract has been shown to alter GLP-1 secretion; particularly when this intestinal manipulation is designed to aid weight reduction. GLP-1 dynamics are altered by bariatric surgery, with an improved secretory response to nutrient intake. However, there remains debate on the mechanisms responsible for the alterations in GLP-1 dynamics.
Here we review the evidence for GLP-1 dynamics after Roux-en-Y gastric bpyass (RYGB), adjustable gastric banding (AGB), biliopancreatic diversion (BPD) and sleeve gastrectomy (SG), and make comparisons between modalities. In addition, we review the potential mechanisms underlying these dynamics, other molecules that may add to the “incretin effect” and other possible roles for GLP-1 following bariatric surgery. Finally, we will offer our critique of the evidence base.
Keywords: Bariatric surgery, Glucagon-like peptide-1, GLP-1, Incretins, glucose tolerance, sleeve gastrectomy, Biliopancreatic diversion, adjustable gastric banding, Roux-en-Y gastric bpyass, duodenal switch , homeostasis.
Current Diabetes Reviews
Title:Glucagon Like Peptide-1 (GLP-1) Dynamics Following Bariatric Surgery: A Signpost to a New Frontier
Volume: 9 Issue: 2
Author(s): K. J. Neff, D. O’Shea and C. W. le Roux
Affiliation:
Keywords: Bariatric surgery, Glucagon-like peptide-1, GLP-1, Incretins, glucose tolerance, sleeve gastrectomy, Biliopancreatic diversion, adjustable gastric banding, Roux-en-Y gastric bpyass, duodenal switch , homeostasis.
Abstract: Glucagon like peptide-1 (GLP-1) is one of the gastrointestinal peptides implicated in glycaemic homeostasis. In non-obese individuals with normal glucose tolerance GLP-1 is secreted in response to nutrient intake. However, this GLP- 1 response is generally accepted to be significantly diminished in those with diabetes, obesity or both.
Given that GLP-1 is secreted from enteroendocrine L cells in the intestine, it is not surprising that manipulation of the gastro- intestinal tract has been shown to alter GLP-1 secretion; particularly when this intestinal manipulation is designed to aid weight reduction. GLP-1 dynamics are altered by bariatric surgery, with an improved secretory response to nutrient intake. However, there remains debate on the mechanisms responsible for the alterations in GLP-1 dynamics.
Here we review the evidence for GLP-1 dynamics after Roux-en-Y gastric bpyass (RYGB), adjustable gastric banding (AGB), biliopancreatic diversion (BPD) and sleeve gastrectomy (SG), and make comparisons between modalities. In addition, we review the potential mechanisms underlying these dynamics, other molecules that may add to the “incretin effect” and other possible roles for GLP-1 following bariatric surgery. Finally, we will offer our critique of the evidence base.
Export Options
About this article
Cite this article as:
Neff J. K., O’Shea D. and le Roux W. C., Glucagon Like Peptide-1 (GLP-1) Dynamics Following Bariatric Surgery: A Signpost to a New Frontier, Current Diabetes Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/1573399811309020001
DOI https://dx.doi.org/10.2174/1573399811309020001 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic:Beta Cell Imaging - Why we need it and what has been Achieved (Executive Editor: Martin Gotthardt)]
Current Pharmaceutical Design Effect of Adding Proprioceptive Exercise to Balance Training in Older Adults with Diabetes: A Systematic Review
Current Diabetes Reviews Pain and Child: A Translational Hypothesis on the Pathophysiology of a Mild Type-2 Diabetes Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti Inflammatory and Anti Arthritic Activity of Different Milk Based Formulation of Curcumin in Rat Model
Current Drug Delivery Mechanisms of Drug Induced QT Interval Prolongation
Current Drug Safety Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) Discovery of Novel Genes Mediating Glucose and Lipid Metabolisms
Current Protein & Peptide Science A Review of the Hypoglycemic Effects of Five Commonly Used Herbal Food Supplements
Recent Patents on Food, Nutrition & Agriculture Screening for Liver Disease - are LFTs Old HAT?
Current Medicinal Chemistry Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer
Current Drug Metabolism Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio as Biomarkers for Cardiovascular Surgery Procedures: A Literature Review
Reviews on Recent Clinical Trials Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Evaluation of the Effect of Nimodipine o.d. (Extended Release) vs Nimodipine t.i.d. in the Treatment of Peripheral Vertigo
Current Drug Delivery Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives
Current Diabetes Reviews The Role of Unbound Drug in Pharmacokinetics/Pharmacodynamics and in Therapy
Current Pharmaceutical Design A Brief Overview of the Oral Delivery of Insulin as an Alternative to the Parenteral Delivery
Current Molecular Medicine Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Oxidative Stress and Neurodegenerative Diseases: Looking for a Therapeutic Solution Inspired on Benzopyran Chemistry
Current Topics in Medicinal Chemistry